Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru

• Published in: Vaccine Vol. 33; pp. A154 - A166
• Main Authors: Mezones-Holguin, Edward, Canelo-Aybar, Carlos, Clark, Andrew David, Janusz, Cara Bess, Jaúregui, Bárbara, Escobedo-Palza, Seimer, Hernandez, Adrian V, Vega-Porras, Denhiking, González, Marco, Fiestas, Fabián, Toledo, Washington, Michel, Fabiana, Suárez, Víctor J
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 07.05.2015; Elsevier Limited
• Subjects: Allergy and Immunology; Child, Preschool; Children; Cost effectiveness; Cost-Benefit Analysis; Disability adjusted life years; Fatalities; Health Policy; Humans; Immunization; Immunization Programs; Infant; Infant, Newborn; Meningitis; Models, Statistical; Mortality; Peru; Peru - epidemiology; Pneumococcal conjugate vaccine; Pneumococcal Infections - economics; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - economics; Pneumococcal Vaccines - immunology; Pneumonia; Prevention; Sensitivity analysis; Streptococcus pneumoniae; Vaccination - economics; Vaccination - methods; Vaccines; Peru; Pneumococcal conjugate vaccine; Children; Cost effectiveness; Peru; Disability adjusted life years
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.12.039

Highlights • Pneumococcal conjugate vaccines (PCV) help to prevent pneumococcal diseases (PD). • PCV13 reduces more cases of severe PD, deaths and sequelae than PCV10. • PCV10 prevents more AOM cases than PCV13. • Separately, both PCV13 and PCV10 showed to be cost-effective in Peru. • Overall, PCV13 is more cost-effective than PCV10 for the Peruvian context, showing an extended dominance.